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Abstract
Objective: To explore the best interventions and working patterns of clinical pharmacists in pediatrics and to determine the
effectiveness of clinical pharmacists in pediatrics.
Methods: We conducted a randomized controlled trial of 160 pediatric patients with nerve system disease, respiratory
system disease or digestive system disease, who were randomly allocated into two groups, with 80 in each group.
Interventions by clinical pharmacists in the experimental group included answering questions of physicians and nurses,
giving advice on treating patients, checking prescriptions and patient counseling at discharge. In the control group, patients
were treated without clinical pharmacist interventions.
Results: Of the 109 interventions provided by clinical pharmacists during 4 months, 47 were consultations for physicians
and nurses, 31 were suggestions of treatment, with 30 accepted by physicians (96.77%) and 31 were medical errors found in
641 prescriptions. Five adverse drug reactions were submitted to the adverse drug reaction monitoring network, with three
in the experimental group and two in the control group. The average length of stay (LOS) for patients with respiratory
system diseases in the experimental group was 6.45 days, in comparison with 10.83 days in the control group, which was
statistically different (p value,0.05); Average drug compliance rate in the experimental group was 81.41%, in comparison
with 70.17% of the control group, which was statistically different (p value,0.05). Cost of drugs and hospitalization and rate
of readmission in two weeks after discharge in the two groups were not statistically different.
Conclusion: Participation by clinical pharmacists in the pharmacotherapy of pediatric patients can reduce LOS of patients
with respiratory system disease and improve compliance rate through discharge education, showing no significant effects
on prevention of ADR, reduction of cost of drugs and hospitalization and readmission rate in two weeks.
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Introduction
Many drugs used in children are done so unlicensed, off-label,
unsafely or without any evidence of efficacy in children [1]. A
report of WHO in 2005 showed three times more medical errors
in children than in adults [2]. Suitable pediatric formulations and
doses in children are required, especially for drugs with a narrow
therapeutic index, which leads to serious morbidity or mortality
when used at a 10-fold dosage [3]. Thus greater focus on
improvement of safety of drugs used in children is necessary.
It was reported that clinical pharmacist participation in the
medical care of patients could improve the safety of drugs [4–5].
Having a pharmacist on a rounding team in an intensive care unit
(ICU) has been shown to reduce the incidence of adverse drug
events (ADEs) by two thirds [6]. A prospective study by Fortescue
et al. showed that ward-based clinical pharmacists prevented 81%
of potentially harmful medication errors [7]. Thus, clinical
pharmacists can not only improve drug safety, but also serve to
lower costs [8], improve quality of pharmacotherapy [9],
coordinate the relationship of Pharmacy with other departments
[10] and enrich patient drug knowledge [11].
Nevertheless, it is difficult to determine the important role of
clinical pharmacists in pediatrics. Studies by Devlin [12] and Dice
[13] on the effects of participation of clinical pharmacists in
treatment of Total Parenteral Nutrition (TPN) showed that
pharmacist-monitored TPN proved cost effective in comparison
with the standardized solution without pharmacist monitoring.
However, a study by Gibson demonstrated that the results of
clinical pharmacists’ involvement in pharmacotherapy [14] were
not statistically different. A systematic review of 18 observational
studies by Navneet [15] highlighted the importance of pharmacists
to medicine management in pediatric patients, but there have not
been any randomized controlled trials so far [15].
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pediatric patients with common diseases to answer the following
questions:
1. What types of interventions do clinical pharmacists provide?
2. Can participation of clinical pharmacists in the medical care of
inpatients reduce the cost of drugs and hospitalization, LOS
and readmission rate and improve patient compliance rate
after discharge?
Methods
The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see Checklist S1 and
Protocol S1. The trial was approved by Ethics Committee of West
China Second University Hospital, Sichuan University and
registered in Chinese Clinical Trial Registry and the registered
number was ChiCTR-TRC-10001081. Patients had given their
written informed consents.
2.1 Study site location and participants
This randomized controlled trial was conducted at West China
Second University Hospital, Chengdu, Sichuan, China, from
December 1, 2010, through to March 31, 2011. Eligible
participants were pediatric patients with nerve system disease,
respiratory system disease, or digestive system disease, whose age
ranged from birth to 18 years old. ‘‘Nerve system disease’’ defined
as epilepsy, cephalomeningitis, intracranial infection, hyperspas-
mia, infantile spasms; ‘‘Respiratory system disease’’ defined as
infection of upper respiratory tract, pneumonia and bronchitis;
‘‘Digestive system disease’’ defined as diarrhiea, gastrointestinal
hemorrhage, esophagitis, gastritis, enteritis. Every patient or
patient’s family was asked to give written informed consent. Those
who were critical or could not speak Chinese or whose families
declined to participate in the trial were excluded.
2.2 Study design
2.2.1 Randomization and concealing allocation. Rando-
mization was completed by SPSS 16.0-generated algorithm.
Treating assignments, kept in sealed opaque envelopes with only
number labeled, were opened after patient gave their informed
consents. One of the two clinical pharmacists distributed envelopes
and recorded patients in each group enrollment and patient
assignment.
2.2.2 Blinding. Patients and clinical pharmacists were aware
of the interventions while trial research assistants and statisticians,
responsible for outcome recording and data analysis, respectively,
were blinded to treatment assignment.
2.2.3 Follow up. The protocol planned that patients were
interviewed 3 or 4 days after discharge. But the compliance rate is
connected with whether the drug courses have finished. Therefore,
time of follow-up was determined by how long the discharge drugs
were used. Patients were usually interviewed on phone when
discharge drugs were half finished.
2.3 Clinical pharmacists’ interventions
2.3.1 Experimental group. In the morning shift, clinical
pharmacists made rounds together with doctors in charge and
provided interventions, which included an assessment of the
patients’ medication, diagnosis, experimental index and drug
treatment. Additionally, they gave advice on drug selections in
view of therapeutic guidelines, the national essential medicine list
and national basic insurance medicine catalogs, provided
pharmacokinetic consultations and drug information for
physicians and nurses, checked prescriptions and communicated
with physicians about any medication errors, reviewed the
indications, directions for use, and possible adverse effects of
each discharge medication and gave discharge education to
patients.
2.3.2 Control group. Patients randomized to the control
group were treated following the traditional medical model, in
which physicians and nurses were responsible for treatment and
clinical pharmacists were excluded from pharmacotherapy and
discharge education.
2.4 Primary outcomes
2.4.1 Interventions by clinical pharmacists. Three types
of interventions were documented by two clinical pharmacists: 1.
answering questions of physicians and nurses; 2. suggestions of
treatment; 3. prevention of medication errors. Answering the
questions of physicians and nurses meant that clinical pharmacists
gave an accepted answer to questions related to drugs by
physicians and nurses. Suggestion of treatment referred to advice
by clinical pharmacists on patient’s treatment which was adopted
by physicians. Prevention of medication errors meant that clinical
pharmacist checked the prescriptions and noted the medication
errors which were corrected by physicians. Of the 109
interventions, 46 were on antibiotics, accounting for 42.2%; 21
on drugs for digestive system, 18 on drugs for respiratory system,
13 on drugs for nerve system, 4 on glucocorticoid, 4 on drugs for
dermatopathya, 2 on electrolyte and 1 on drug for hematologic
system. This measurement was not only the different interventions
between experimental group and controlled group but also the
crucial factor relative to repeatability and reproducibility of this
trial. The clinical pharmacists did not participate in the treatment
of patients in controlled group, so we only recored the
interventions in patients in experimental group.
2.4.2 The number of adverse drug reactions
(ADR). Clinical pharmacists detected ADRs in the
experimental group while the physicians and nurses detected
that in the control group.
2.4.3 Length of stay. Length of stay (LOS) refers to the
number of days staying in hospital from admission to discharge.
2.4.4 Cost of drugs. Cost of drugs includes total charges of
Western medicines and Chinese traditional medicines.
2.4.5 Cost of hospitalization. Cost of hospitalization is
defined as total charges in the hospital, including cost of drugs,
examining and nursing care.
2.5 Secondary outcomes
2.5.1 Compliance rate. The method by Williford and
Johnson [16] was adopted in terms of measurement of
compliance rate. In accordance with the time set in the method,
clinical pharmacists interviewed patients on phone in the follow-up,
asking the followingquestions: 1. to state the name of eachmedicine
prescribed at discharge; 2. to state the therapeutic action of each
medicine; 3. to state the usage of each medicine at discharge; and 4.
to state the administration of the drug taken at present
Compliance rate~the number of right answers=
the total number of drugs  4 questions
2.5.2 Readmission rate. Readmission rate referred to the
proportion of patients readmitted to hospital in two weeks after
discharge of the total patients.
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Intention to treat (ITT) was used to analyze the data. Statistical
software SPSS 16.0 was used for all analyses. Continuous
parametric length of stay, compliance rate and readmission rate
were analyzed by student’s t-test. The values, like age of patients,
cost of drugs and hospitalization, which were not normal
distribution were analyzed by nonparametric test Wilcoxon rank
sum test. Discrete data was analyzed with chi-square test. Results
with a p value,0.05 were considered statistically significant.
Subgroup analysis was adopted for LOS according to different
types of diseases such as nerve system disease, digestive system
disease and respiratory system disease. Multiple linear regression
analysis was used to explore the relationship between compliance
rate and age of patients, number of discharge drugs and time of
follow up. Of the seven indexes, interventions of clinical
pharmacists were descriptive index, and thus could not be counted
in as samples. While it was reported in some literatures that rate of
ADR decreased in the group with clinical pharmacists, other
studies found that with interventions of clinical pharmacists, the
rate increased. Thus, We could not determine whether interven-
tions of clinical pharmacists could decrease the rate of ADR It was
the same case for the length of stay; in terms of cost of drugs and
hospitalization,which was nonparametric distribution data, they
were lack of mean value. Therefore, compliance rate alone was
used to power calculation.
Compliance rate was reported to be 75% in the literatures [16–
17]. In our study, clinical pharmacists in pediatric unit were trying
to improve the compliance rate to 95%. In order to achieve such a
result, we set a power of 90% and the 5% level of significance
(a=0.05, b=0.1). Through calculation, we found that this
required 67 patients in both groups. With 20% loss of follow-up
considered, a total of 160 patients were required, with 80 in each
group.
Results
We recruited 160 patients to this study. Inclusion procedures
are illustrated in Figure 1. The 160 patients were randomly
allocated to the experimental group and the control group, with 80
in each group. In the experimental group, after two patients gave
up treatment and another two were transferred to other
department, only 76 patients received clinical pharmacists’
intervention. In the control group, after four patients gave up
treatment and another two were transferred to other department,
only 74 patients received usual care. In the phase of follow-up, 16
experimental patients were discharged without drugs and 2 could
Figure 1. Trial flow chart.
doi:10.1371/journal.pone.0030856.g001
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12 patients from the control group were discharged without drugs
and 5 could not be contacted, so 57 received an interview. Trial
flow chart is presented in figure 1.
Characteristics of patients are presented in Table 1. There were
no significant differences between the two groups.
3.1 Primary outcomes
3.1.1 Interventions by clinical pharmacists. Clinical
pharmacists provided 107 interventions. These included 47
questions asked by physicians or nurses, 31 suggestions of
treatment and the prevention of 31 medication errors (Table 2).
During the trial, the 47 questions for clinical pharmacists posed by
doctors and nurses could all be classified into 7 categories:
information of drug production, dosage and administration,
specification, pharmacological actions, management, interaction
and contraindication. Of all the questions, the greatest number
were concerned about dosage and administration, accounting for
55.3%, followed by those about pharmacological actions, for
25.5% and 8.5% questions were about contraindications. Of the
31 suggestions, 64.52% were on drugs selection or discontinuance
and 16.13% on drugs combinations. 71% of the 31 suggestions
were on use of antibiotics. Of the 683 prescriptions checked by
clinical pharmacists, 31 medication errors were found with an
incidence frequency of 4.53%.
3.1.2 The number of adverse drug reaction (ADR). Five
ADRs were identified in the study, with three in the experimental
group and two in the control group. Of the three in the
experimental group, one patient developed rash after taking
rifampicin, another patient’s neutrophile granulocyte count began
to drop after taking Ganciclovir, and the third suffered emesis after
taking oral cough syrup. Of the two patients in the control group,
one was reported to have developed rashes after injection of
tazobactam sodium and the other one was agitated after taking
oral ammonia bromine. The five patients recovered after
discontinuing these drugs. They were submitted to the adverse
reaction monitoring network by clinical pharmacists.
3.1.3 Length of stay. 76 patients in the experimental group
and 74 patients in the control group were analyzed with respect to
LOS. The result showed that mean of LOS in the two groups was
7.33 and 9.06 days respectively, which was statistically different
(Table 3).
Sub-analysis showed that in the patients with nerve system
disease and digestive system disease, LOS in the two groups was
not statistically different (Table 3) while concerning patients with
respiratory system diseases, LOS was statistically different
(Table 3).
3.1.4 Cost of drugs and hospitalization. Through
comparison of cost of drugs and hospitalization between 76
patients in the experimental group and 74 patients in the control
group, a rank sum test demonstrated that cost of drugs and
hospitalization in the two groups were not statistically different
(Table 4).
3.2 Secondary outcomes
In the follow-up, a total of 58 and 57 patients were included into
the experimental and the control group, respectively. A significant
improvement of compliance rate was seen in the experimental
group, in which clinical pharmacists gave discharge education to
patients. Multiple linear regression analysis showed that drug
compliance rate was not related to age, number of drugs, or time
of follow-up, as these showed no statistical differences (Table 5).
We first compared the number of discharge drugs and time of
follow-up in the two groups with consideration to their relevance
to drug compliance rate. The result showed that the average
number of discharge drugs in the two groups was 2.74 and 2.64
respectively, which was not statistically different (P value.0.05)
and that the time interval from discharge to follow-up in the two
groups was 3.69 days and 3.96 days, with a P value.0.05 showing
no statistical differences. There were no significant differences
between the two groups (Table 6). Mean of compliance rate was
81.41% in the experimental group, and 70.17% in the control
group, which was statistically different (P value,0.05, Table 6).
Comparing the readmission rate of patients with respiratory
diseases or digestive system diseases between the experimental
group (44 cases) and the control group (38 cases), showed that
there were 4 patients in the experimental group (9.1%) and 5
patients in the control group (13.2%) that needed outpatient
treatment within 2 weeks after discharge, which was not
statistically different (P value.0.05, Table 5). This result suggested
Table 1. Characteristics of patients.
Characteristic Experimental group(=80) Control group (n=80) P value
Age, No.y
,1 20 21 0.941
1,53 6 3 4
5,10 13 12
.10 11 13
Sex, No.(M/F) 43/37 44/36 0.874
Disease 0.637
Nerve system disease 36 42
Respiratory system disease 29 25
Digestive system disease 15 13
weight(kg) 15.86610.73 16.16611.33 0.864
Temperature(uC) 36.9360.93 36.9260.72 0.909
Pulse(sequence/min) 115622.84 116623.25 0.646
Breath(sequence/min) 28.267.76 29.268.87 0.444
doi:10.1371/journal.pone.0030856.t001
Clinical Pharmacists in Pediatrics
PLoS ONE | www.plosone.org 4 January 2012 | Volume 7 | Issue 1 | e30856that interventions of clinical pharmacists in pharmacotherapy
could not reduce rate of readmission.
Discussion
This study is the first randomized controlled trial on the
effectiveness of clinical pharmacists in pediatric hospitalized
patients. It showed that on the one hand interventions by clinical
pharmacists on pharmacotherapy of pediatric patients were
associated with a significantly shorter LOS and a higher
compliance rate after hospital discharge. On the other hand, no
differences were seen in rate of ADR, cost of drugs and
hospitalization or readmission rate. The shorter LOS in patients
of the experimental group, especially in the patients with
respiratory system disease, may be attributed to suggestions of
treatment, and higher compliance rate after discharge was a result
of discharge education provided by clinical pharmacists.
Clinical pharmacists included into our study had fixed work
hours. In the morning shift, they became familiar with history of
present illness and drugs taken for newly admitted patients. Then
they made rounds with the pediatric team, provided suggestions of
treatment, checked the prescriptions of physicians, gave consulta-
tions to discharged patients. Afterwards, they stood by for calls
throughout the day. The schedule of clinical pharmacists in the
study was similar to that reported by Leape [18] which
investigated pharmacist participation on physician rounds in the
intensive care unit. In their study, Krupicka et al. reported that
clinical pharmacists worked for 5 days a week with weekend
services provided in a centralized location. The clinical pharma-
cists attended morning rounds at least twice per week [19], which
was less than that in our study.
Percentage distribution of clinical pharmacists’ time in each
intervention was not calculated in our study. However, it was
estimated that clinical pharmacists spent 80% of their working
time in providing suggestions, checking the prescriptions, doing
rounds of the ward and giving consultations to the patients. Gibson
[9] reported on distribution of time use by clinical pharmacists in a
pediatric unit: checking doses in patient trays for correctness and
new physician’s orders covered 17.5%, respectively; 12.5% time
was spent in reconciling pharmacy patient profile with nursing,
reference research for drug information, checking unit dose
injections and nursing station visits and supplying first doses
covered 10%, answering questions from nursing staff, reading
patient medical records, calculating pediatric doses, and dispersing
prescriptions for patient discharge covered 5%. Only 2.5% time
was spent in providing suggestions for doctors.
109 interventions were documented in 4 months in our study,
comparatively less than other studies completed abroad. Kucu-
karslan et al. [20] reported that more than 150 interventions were
provided by clinical pharmacists in 3 months. Koren et al. [21]
documented 390 interventions conducted within 2 months in her
studies while Strong and Tsang [22] provided 361 interventions
within 2 weeks.
Two factors could be proposed to explain these findings. First,
other studies included more patients than our study did. For
example, pharmacist: patient ratio was approximately 1:15 in
Kucukarslan et al.’s study [20]. Second, clinical pharmacists in our
study spent less time on clinical treatment, Kucukarslan et al. and
Krupicka et al. documented all interventions that occurred during
Table 2. Interventions by clinical pharmacists.
Interventions No. (%)
1.Answering the question of physicians or nurses
(47)
Information of drug production 1 (2.1%)
Drugs dosage and usage 26 (55.3%)
Drugs specification 1 (2.1%)
Drugs pharmacology 12 (25.5%)
Drugs management 1 (2.1%)
Drugs interaction 2 (4.2%)
Drugs contraindication 4 (8.5%)
2.Suggestion of treatment (31)
Drugs combination 5 (16.13%)
Dosage to add or subtract 3 (9.67%)
Selection or discontinuance drugs 20 (64.52%)
Time of usage 1 (3.22%)
Drug formulation 1 (3.22%)
Prevention of ADR 1 (3.22%)
3.Prevention of medication errors (31)
Prescription errors 12 (38.71%)
Dosage errors 4 (12.91%)
Preparation errors 10 (32.26%)
Technology errors 1 (3.2%)
Compliance errors 4 (2.90%)
doi:10.1371/journal.pone.0030856.t002
Table 3. LOS in the two groups.
Experimental
group Control group P value
No. LOS,D No. LOS,D
Total patients 76 7.3363.52 74 9.0665.47 0.02
Subgroup analysis
Nerve system disease 33 8.3664.15 38 9.7666.32 0.28
Respiratory system disease 29 6.4562.91 24 10.8366.72 0.003
Digestive system disease 14 6.7162.43 12 6.0863.11 0.57
doi:10.1371/journal.pone.0030856.t003
Table 4. Cost of drugs and hospitalization in the two groups.
Intervention group
(n=76)
Control group
(n=74) P value
Cost of drugs (RMB, yuan)
,1000 36 35 0.945
1000,3000 24 26
3000,5000 10 4
.5000 6 9
Cost of hospitalization (RMB, yuan)
,2000 18 15 0.125
2000,4000 33 25
4000,6000 10 10
.6000 15 24
doi:10.1371/journal.pone.0030856.t004
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pharmacists in our study were available on call in the afternoon.
Among the 31 suggestions made by clinical pharmacists, 30
(96.77%) were accepted by the treating physicians. Similarly, of
the 48 interventions recorded by Virani and Crown [23], 47 were
adopted. Condren et al. [24] reported that during 12 months 91%
of 4605 interventions performed for 3978 patients were accepted
by the physicians. A lower acceptance rate of 80% was reported in
a study by Guy et al. [25]. These findings demonstrated that
reasonable suggestions provided by clinical pharmacists are
generally accepted by physicians.
During the trial, 31 medical errors in 684 prescriptions were
detected by clinical pharmacists. The frequency of errors was
4.53%, which was higher than other studies. A study conducted by
Folli et al. [26] in two large children’s hospitals in the US found
the frequency of errors was 4.9 and 4.5 errors per 1000 medication
orders. Similar to our study, the frequency of order errors declined
as physician training status increased. The frequency of errors in
Riley Hospital for Children and Indiana University Hospital was
2.66% (1277/48034) and 1.34% (1012/75333), respectively. The
most common types of errors in our study were prescription and
preparation errors while the most common types in other studies
were wrong dose and inappropriate dosage schedule [19,22].
Of the five ADR, four were detected in the hospital, and one
was detected during follow up. The incidence rate of ADR, 3.33%,
was less than the overall, 6.20%, as reported in a systematic review
[27]. This suggests that more attentions should be paid to ADRs in
children.
Like the other three studies, our findings demonstrate the
significant role of clinical pharmacists in reduction of LOS of
patients. The three randomized trials demonstrated that partici-
pation by clinical pharmacists in pharmacotherapy could reduce
length of stay by 1.3 days (18.05%), to 4.4 days (30.35%), which
was statistically significant [28–30]. One controlled study on a
large sample (n=7219) showed that clinical pharmacists could
reduce LOS by 2.4 days (18.18%), which was statistically different
[31]. A retrospective study showed that clinical pharmacists
reduced LOS by 5.99 days (31.39%), but in the study only 23 cases
were included as interventions [32]. Nevertheless, some studies still
show that participation of clinical pharmacists in pharmacother-
apy does not cause a statistically significant decrease in LOS [33–
37]. Research by Lal, Anassi and McCants [10] demonstrated that
clinical pharmacists participating in pediatric pharmacotherapy
conducted 504 interventions, which reduced LOS from 4.38 days
to 4.26 days. Through analysis of results in the subgroup, we found
that with participation of clinical pharmacists in treatment of
patients with respiratory diseases LOS in the two groups was
statistically different, while in treatment of patients with neuro-
logical and digestive diseases, LOS was not statistically different.
The result may be caused by the fact that over 50% of the more
than 100 interventions were related to drugs on respiratory system
and that most treatment suggestions were on the use of antibiotics.
With different costs of treatment for different diseases, costs of
drugs and hospitalization in the study differed from a normal
distribution. Results by nonparametric test showed no significant
differences. Conversely, research abroad demonstrated that
participation of clinical pharmacists in treatment could reduce
costs of drugs and hospitalization and that there were significant
differences [38]. A study by Lal, Inassi and McCant [10] on
pediatric clinical pharmacists showed that with clinical pharma-
cists’ participation, the cost of treatment of a pediatric inpatient
during 6 months had been reduced by $7227. 83, which
significantly demonstrated the economical efficiency of participa-
tion of clinical pharmacists in drug treatment of patients.
Failure to comply with medication instructions commonly led to
serious adverse outcomes, and noncompliance after discharge may
place patients at risk for suboptimal response and toxic outcomes,
including readmission to the hospital [39–41]. Patient education
before discharge has been recognized a valuable method to
improve compliance of patients [42,43]. Our study demonstrated
that patient education could increase the compliance rate by
16.02%, which was close to the results of the other three
randomized controlled trials [44,45].
Table 5. Secondary study outcomes.
Intervention Group (n=58) Control group (n=57) P value
Baseline
Discharge drugs, No. 2.7461.58 2.6461.41 0.742
Time of follow-up, day 3.6961.25 3.9661.27 0.243
Compliance rate (%) 81.41619.42 70.17622.33 0.005
Readmission rate, No.(%) 4 (9.1%) 5 (13.2%) 0.726
doi:10.1371/journal.pone.0030856.t005
Table 6. Coefficients.
Variable Unstandardized Coefficients
Standardized
Coefficients t P
B Std. Error
Constant 86.339 7.072 12.208 0.000
Age 20.041 0.042 20.092 20.984 0.327
No. of drugs 22.082 1.373 20.144 21.517 0.132
Time of follow-up 20.795 1.633 20.046 20.487 0.627
doi:10.1371/journal.pone.0030856.t006
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compliance rate and the age of patients, time of follow-up and
number of discharge drugs. Other studies demonstrated a major
factor associated with noncompliance in discharged patients was
the complexity of the prescribed regimen [16,39]. Several reasons
could be considered. First, the people interviewed in follow-up
were families of patients. Secondly, the time of follow-up was fixed,
approximately 3 to 4 days after discharge. Thirdly, most patients
were prescribed comparatively fewer drugs upon discharge, from
one to six.
Readmission rate in two weeks after discharge in our study was
9.1% and 13.2% in experimental and control group, respectively.
Different readmission rates have been reported in different
diseases, from 4.58% to 39% [30,46–47]. Different time of
follow-up was also associated with readmission rate. Al Rashed
[48] reported that readmission rate in two or three weeks after
discharge was 11.6% in experimental group and 32.5% in the
control group. There was significant difference between the two
groups. No significant difference was showed in the readmission
rate at 30 days or 3 months after discharge in both groups [46,47].
Seasonal bias was little in our trial. Our trial lasted five months,
(December 2010—April 2011), from winter to spring. We
investigated the diseases of patients in the department for
incidence of diseases in summer and autumn. The result showed
that there were 374 cases in summer and 363 ones in autumn. Of
the cases in summer, 194 were nerve system disease, 112
respiratory system diseases, and 66 digestive system disease.
Comparatively, of the cases in autumn, 198 were nerve system
diseases, 86 respiratory system diseases and 79 digestive system
diseases. Incidences of diseases of nerve system, respiratory system
and digestive system in the four seasons were not statistically
different. P=0.114.
There are still limitations in our study. First, clinical pharmacists
did not participate in treatment of patients in the control group,
but in fact, clinical pharmacists also provided suggestions for
patients in the control group when the physicians consulted them,
which led to contamination and interference of results of the two
groups. Second, the clinical pharmacists also participated in
treatment of patients with serious disease who were excluded in the
trial, but the interventions were not documented. Therefore, the
number of interventions was more than what were recorded in this
trial. Third, the power of test in patients with nerve system disease
and digestive system disease were 0.29 and 0.1 respectively,
indicating that the sample size was not enough. Nevertheless, as
this trial was only an exploratory study, we will expand the sample
size in the subsequent studies to observe whether difference exists
Conclusion
1. The participation of clinical pharmacists in pharmacotherapy
of pediatric patients can reduce length of stay of patients with
respiratory system disease and improve compliance rate
through discharge education.
2. Our study did not find significant effect of clinical pharmacists
on prevention of ADR, reduction of cost of drugs and
hospitalization or readmission rate in two weeks.
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